252 related articles for article (PubMed ID: 31396671)
21. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
22. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
24. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
Guglielmelli P; Pacilli A; Rotunno G; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pietra D; Salmoiraghi S; Mannarelli C; Franci A; Paoli C; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM;
Blood; 2017 Jun; 129(24):3227-3236. PubMed ID: 28351937
[TBL] [Abstract][Full Text] [Related]
25. Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis.
Hussein K; Stucki-Koch A; Kreipe H
Ann Hematol; 2018 Nov; 97(11):2099-2106. PubMed ID: 29961094
[TBL] [Abstract][Full Text] [Related]
26. [18F-FDG-PET/CT is effective in distinguishing myelofibrosis due to bone marrow infiltration of diffuse large B-cell lymphoma from triple-negative primary myelofibrosis].
Kumagai T; Satoh Y; Koshiishi M; Ooishi S; Sueki Y; Nakajima K; Mitsumori T; Kirito K
Rinsho Ketsueki; 2017; 58(3):228-232. PubMed ID: 28381690
[TBL] [Abstract][Full Text] [Related]
27. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia.
Longmore G; Guinan EC; Weinstein HJ; Gelber RD; Rappeport JM; Antin JH
J Clin Oncol; 1990 Oct; 8(10):1707-14. PubMed ID: 2213106
[TBL] [Abstract][Full Text] [Related]
30. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
31. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
Thota S; Gerds AT
Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
[TBL] [Abstract][Full Text] [Related]
33.
Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Patel K; Ganan-Gomez I; Jabbour E; Kadia T; Ravandi F; DiNardo C; Borthakur G; Takahashi K; Konopleva M; Komrokji RS; DeZern A; Kuzmanovic T; Maciejewski J; Pierce S; Colla S; Sekeres MA; Kantarjian H; Bueso-Ramos C; Garcia-Manero G
Blood Adv; 2019 Mar; 3(6):922-933. PubMed ID: 30902805
[TBL] [Abstract][Full Text] [Related]
34. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
35. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
36. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
37. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.
Maschek H; Georgii A; Kaloutsi V; Werner M; Bandecar K; Kressel MG; Choritz H; Freund M; Hufnagl D
Eur J Haematol; 1992 Apr; 48(4):208-14. PubMed ID: 1592101
[TBL] [Abstract][Full Text] [Related]
38. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
39. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
40. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
